MedPath

Investigation of Microbiome-Derived Metabolite Production in Response to a Mediterranean Diet

Not Applicable
Completed
Conditions
Food Habits
Interventions
Other: Mediterranean diet
Registration Number
NCT03783260
Lead Sponsor
Laval University
Brief Summary

This project proposes to characterise the microbiome-derived metabolites produced upon ingestion of bioactive precursor-rich meals by healthy volunteers in order to investigate the relationship between gut microbiome composition and the nature of dietary metabolites production.

Detailed Description

There is a large inter-individual variability in gut microbiome-derived metabolites production upon ingestion of similar meals. Since many of these microbiome-derived metabolites have enteric and systemic biological effects, these variabilities could in part account for the different responses to meals and diets.

This project thus aims to improve the understanding the relationship between gut microbiome composition and the nature of dietary metabolites produced from similar bioactive precursor-rich meals.

The investigators therefore propose to characterise the circulating microbiome-derived metabolite profiles in healthy individuals fed the same 2-day precursor-rich Mediterranean diet prior to and after a 2-week of habitual Canadian diet feeding.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
21
Inclusion Criteria
  • Men and women aged between 18 and 35 years
  • Body mass index between 18.5 and 30 kg/m2
  • General good health
  • Computer and Internet access
  • Basic understanding of written French
Exclusion Criteria
  • Intestinal pathologies including inflammatory bowel disease and gastrointestinal cancers
  • Pregnant and/or breast-feeding women
  • Alcohol consumption greater than 15 portions for men and 10 for women weekly
  • Active tobacco usage
  • Consumption of dietary supplements (e.g. multivitamins, omega-3, probiotics)
  • Completion of a course of antibiotics in the past 3 months
  • Regular use of anti-inflammatory drugs, or use in the past 3 months
  • Important weight change (+/- 5 kg) in the past 6 months
  • Allergies or food intolerances to ingredients present in trial diets

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
SingleMediterranean dietAll participating subjects will undergo two, 2-day Mediterranean diet feeding periods separated by a 14-day period of Canadian diet
Primary Outcome Measures
NameTimeMethod
Microbiome-derived metabolite profiling19 days

Plasma and urine metabolomics profiling of gut-microbiome derived metabolites (e.g., branched-chain amino acids \[BCAA\], short chain fatty acids \[SCFA\], trimethylamine \[TMA\], amino acids- and polyphenol-metabolites) will also performed at the same time points.

Gut microbiome characterisation19 days

Fecal microbiome composition will be characterise by rRNA 16S sequencing prior to and following both 2-day Mediterranean diet periods. Relevant indexes of microbiome diversity (e.g. Shannon beta-diversity), ratios between meaningful bacterial markers of gut dysbiosis (e.g. Firmicutes:Bacteroidetes) and specific microbiome differences in bacterial Families, Genera or species between study periods and individuals.

Secondary Outcome Measures
NameTimeMethod
Endocannabinoid interaction with interindividual microbiome composition19 days

Interindividual variations in the endocannabinoid levels following a 2-day Mediterranean diet intervention according to individual gut microbiome composition will also be characterised. N-acyl ethanolamines, acylglycerols and omega-3 derived endocannabinoids will be quantified by LC MS-MS in plasma and urine samples collected prior to and following both 2-day Mediterranean diet periods.

Trial Locations

Locations (1)

Institut sur la nutrition et les aliments fonctionnels - INAF

🇨🇦

Québec, Quebec, Canada

© Copyright 2025. All Rights Reserved by MedPath